- Home
- ABOS vs LANV Comparison
ABOS vs LANV Comparison
Compare ABOS & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABOS | LANV |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | China |
| Employees | N/A | 2066 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 178.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABOS | LANV |
|---|---|---|
| Price | $2.24 | $1.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 353.9K | 8.9K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $1.03 |
| 52 Week High | $3.60 | $2.54 |
Technical Indicators
Market Signals| Indicator | ABOS | LANV |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 35.81 |
| Support Level | $2.13 | $1.03 |
| Resistance Level | $2.43 | $1.76 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 53.33 | 9.37 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.